82 results
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
11 Dec 19
Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol
9:00am
Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development … for our product candidate, risks relating to our growth strategy; risks relating to the results of research and development activities; risks relating
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
14 Jun 21
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
9:00am
statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements … on our employees’ and consultants’ ability to complete work in a timely manner, risks relating to our growth strategy; risks relating to the results
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
17 Dec 20
Avenue Therapeutics Provides Regulatory Update for IV Tramadol
9:02am
growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based … ’ and consultants’ ability to complete work in a timely manner, risks relating to our growth strategy; risks relating to the results of research
8-K
ATXI
Avenue Therapeutics Inc
1 Aug 19
Departure of Directors or Certain Officers
9:00am
in pharmaceuticals, biotech, device strategy and marketing. Ms. Ingram joined Cipla USA, Inc. in July 2019 as Chief Commercial Officer, Specialty Hospital … 2014 to 2016. Prior to joining Sanofi, she held the position of Vice President of Market Access Strategy at Bristol Myers Squibb, where she led
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
13 Oct 20
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
6:10am
as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any … , risks relating to our growth strategy; risks relating to the results of research and development activities; risks relating to the timing
8-K
EX-99.1
g2f1htw4fpa8xaj7pxy6
14 Nov 18
Avenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
4:31pm
8-K
EX-99.1
ypqswv2lfwygq
14 Aug 20
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
8:30am
8-K
EX-99.1
k24ub hhm9bq
13 Feb 20
Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA
9:15am
8-K
EX-99.1
mru2uksi684i94
3 Jun 19
Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain
8:45am
8-K
EX-99.1
lehxk6hn
3 May 18
Avenue Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
8:00am
8-K
EX-99.1
5tsntbnkumus2t30gtqg
30 Mar 20
Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights
9:01am
8-K
EX-99.1
ouiy c7z0qcopvna9
16 Feb 22
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol
7:39am
8-K
EX-99.1
f2xzijkssyal7bm8orwr
13 May 19
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
9:00am
8-K
EX-99.1
87keyzf7zyl7g2wj8
4 Nov 19
Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
9:00am
8-K
EX-99.1
ctkr8 cal2pfx
23 Apr 20
Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters
9:00am
8-K
EX-99.1
x3nshdr
14 Aug 19
Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
12:00am
8-K
EX-99.1
gviau6x94ai
11 May 20
Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
9:00am
DEFA14A
0dilcb s9
29 May 20
Additional proxy soliciting materials
9:30am
8-K
EX-99.1
7eez sviwiak2wmqoi
14 Aug 18
Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
9:00am
8-K
EX-99.1
rrmf0iuwjguly6
12 Mar 19
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights
9:16am